Several forms of cancer are associated with either overexpression or perpetual activation of the protein FGFR3. A new paper now provides evidence that FGFR3 might be a good therapeutic target for these cancers and describes the development of an FGFR3-targeted antibody that had potent antitumor activity in mice transplanted with human tumor cells expressing either too much or overactive FGFR3.